Literature DB >> 19285271

Risk stratification for cancer-associated venous thromboembolism.

Gregory C Connolly1, Alok A Khorana.   

Abstract

The risk of venous thromboembolism (VTE) is elevated in cancer, and thrombosis is the second leading cause of death in patients with malignancy. Many risk factors for cancer-associated thrombosis have been identified. These include patient-associated factors such as age, obesity and medical comorbidities; cancer-associated factors such as site and stage of cancer; and treatment-associated factors, particularly chemotherapy and hospitalization. In addition, several candidate biomarkers for cancer-associated thrombosis have been identified recently. Despite the high rate and significant impact of VTE in cancer outpatients, prior attempts at thromboprophylaxis in this population have not consistently demonstrated a benefit. This chapter will focus on risk stratification approaches, including a recently developed predictive model which can be used to identify those patients at highest risk. This model-based approach may have a significant impact on cancer-related morbidity, mortality and cost of care by directing targeted thromboprophylaxis in the future.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19285271     DOI: 10.1016/j.beha.2008.12.006

Source DB:  PubMed          Journal:  Best Pract Res Clin Haematol        ISSN: 1521-6926            Impact factor:   3.020


  13 in total

1.  Evaluation of procoagulant tissue factor expression in canine hemangiosarcoma cell lines.

Authors:  Lauren E Witter; Erika J Gruber; Fabian Z X Lean; Tracy Stokol
Journal:  Am J Vet Res       Date:  2017-01       Impact factor: 1.156

Review 2.  Apixaban Use in Obese Patients: A Review of the Pharmacokinetic, Interventional, and Observational Study Data.

Authors:  Michael J Jamieson; Wonkyung Byon; Richard W Dettloff; Matthew Crawford; Peter S Gargalovic; Samira J Merali; Joelle Onorato; Andres J Quintero; Cristina Russ
Journal:  Am J Cardiovasc Drugs       Date:  2022-05-16       Impact factor: 3.571

Review 3.  The role of platelets in tumour growth.

Authors:  K Pilatova; L Zdrazilova-Dubska; G L Klement
Journal:  Klin Onkol       Date:  2012

Review 4.  The prothrombotic activity of cancer cells in the circulation.

Authors:  Annachiara Mitrugno; Garth W Tormoen; Peter Kuhn; Owen J T McCarty
Journal:  Blood Rev       Date:  2015-07-14       Impact factor: 8.250

5.  Risk of venous thromboembolism in cancer patients treated with epoetins or blood transfusions.

Authors:  Antonios Douros; Kathrin Jobski; Bianca Kollhorst; Tania Schink; Edeltraut Garbe
Journal:  Br J Clin Pharmacol       Date:  2016-06-22       Impact factor: 4.335

6.  Increased Incidence of Venous Thromboembolism with Cancer Immunotherapy.

Authors:  Joanna Roopkumar; Shadi Swaidani; Ann S Kim; Bicky Thapa; Lorenzo Gervaso; Brian P Hobbs; Wei Wei; Tyler J Alban; Pauline Funchain; Suman Kundu; Naseer Sangwan; Patricia Rayman; Paul G Pavicic; C Marcela Diaz-Montero; John Barnard; Keith R McCrae; Alok A Khorana
Journal:  Med (N Y)       Date:  2021-03-12

7.  Plasma free fatty acid levels influence Zn(2+) -dependent histidine-rich glycoprotein-heparin interactions via an allosteric switch on serum albumin.

Authors:  O Kassaar; U Schwarz-Linek; C A Blindauer; A J Stewart
Journal:  J Thromb Haemost       Date:  2014-11-22       Impact factor: 5.824

8.  Prognostic value of routine laboratory variables in prediction of breast cancer recurrence.

Authors:  Zhu Zhu; Ling Li; Zhong Ye; Tong Fu; Ye Du; Aiping Shi; Di Wu; Ke Li; Yifan Zhu; Chun Wang; Zhimin Fan
Journal:  Sci Rep       Date:  2017-08-15       Impact factor: 4.379

Review 9.  The potential benefits of low-molecular-weight heparins in cancer patients.

Authors:  Francisco Robert
Journal:  J Hematol Oncol       Date:  2010-01-14       Impact factor: 17.388

10.  Association of Peripheral Monocyte Count with Soluble P-Selectin and Advanced Stages in Nasopharyngeal Carcinoma.

Authors:  Adi Surya Komala; Andhika Rachman
Journal:  Adv Hematol       Date:  2018-03-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.